As Yervoy Launch Nears, Pricing Of Maintenance Therapy Remains A Key Question

FDA’s approval of Bristol-Myers Squibb’s Yervoy (ipilimumab) for unresectable or metastatic melanoma March 25 grabbed attention for several reasons – the monoclonal antibody is the first new treatment approved for advanced melanoma in 13 years and the first ever to demonstrate a survival benefit.